Todd W Miller, PhD
Adjunct Professor of Molecular and Systems Biology
Co-Director, Cancer Signaling, Genomes & Networks Research Program, Dartmouth Cancer Center
Scientific Director, Comprehensive Breast Program, Dartmouth Cancer Center
Co-Director, Molecular Tumor Board, Dartmouth Cancer Center
Molecular and Systems Biology
University of Connecticut (Storrs, CT), B.S., Physiology & Neurobiology, 1998
University at Albany (Albany, NY), Ph.D. in Biomedical Sciences, 2004
Vanderbilt University (Nashville, TN), Post-doctoral Fellowship in Breast Cancer, 2004-2009
Molecular and Cellular Biology Graduate Programs
Norris Cotton Cancer Center
1 Medical Center Drive
Rubin Bldg, HB 7936
Lebanon NH 03756
Office: Rubin 604
Breast cancer, targeted therapeutics, signaling pathways, drug resistance, biomarker development
Dr. Miller received his B.S. in Physiology and Neurobiology at the University of Connecticut in 1998, and his Ph.D. in Biomedical Sciences at the State University of New York at Albany in 2004 (thesis: Immunization and single-chain Fv intrabody gene therapies for Huntington’s Disease). He did his postdoctoral training at Vanderbilt University (2004-2009), and served as a Research Faculty member 2009-2012. Dr. Miller joined the Geisel School of Medicine at Dartmouth in 2012.
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression.
The role of cancer cell bioenergetics in dormancy and drug resistance.
Alpelisib Efficacy without Cherry-PI3King Mutations.
Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients.
High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
Pan-Cancer Transcriptional Models Predicting Chemosensitivity in Human Tumors.
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.